NO20063017L - Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer - Google Patents
Protein NMB0928 og anvendelse derav i farmasoytiske formuleringerInfo
- Publication number
- NO20063017L NO20063017L NO20063017A NO20063017A NO20063017L NO 20063017 L NO20063017 L NO 20063017L NO 20063017 A NO20063017 A NO 20063017A NO 20063017 A NO20063017 A NO 20063017A NO 20063017 L NO20063017 L NO 20063017L
- Authority
- NO
- Norway
- Prior art keywords
- formulations
- origin
- ability
- diseases
- nmb0928
- Prior art date
Links
- 101100431363 Neisseria meningitidis serogroup B (strain MC58) NMB0928 gene Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2002008620030286A CU23236A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P |
PCT/CU2004/000016 WO2005054282A1 (es) | 2003-12-03 | 2004-12-02 | Proteína nmb0928 y su uso en formulaciones farmaceuticas |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063017L true NO20063017L (no) | 2006-09-01 |
Family
ID=40091627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063017A NO20063017L (no) | 2003-12-03 | 2006-06-28 | Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070128230A1 (es) |
EP (1) | EP1693379B1 (es) |
KR (1) | KR20060124625A (es) |
CN (1) | CN100549027C (es) |
AR (1) | AR046937A1 (es) |
AT (1) | ATE456573T1 (es) |
AU (1) | AU2004294377A1 (es) |
BR (1) | BRPI0417334A (es) |
CA (1) | CA2547537A1 (es) |
CU (1) | CU23236A1 (es) |
DE (1) | DE602004025377D1 (es) |
NO (1) | NO20063017L (es) |
NZ (1) | NZ547521A (es) |
RU (1) | RU2335505C2 (es) |
WO (1) | WO2005054282A1 (es) |
ZA (1) | ZA200604492B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23549A1 (es) * | 2005-12-29 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas que contienen la proteína nma0939 |
CU23572A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0938 |
CU23575A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0606 |
CN109890413B (zh) | 2016-09-02 | 2024-04-16 | 赛诺菲巴斯德股份有限公司 | 脑膜炎奈瑟氏菌疫苗 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4219821A1 (de) * | 1992-06-17 | 1993-12-23 | Boehringer Mannheim Gmbh | Spezifischer Nachweis von Neisseria Gonorrhoeae |
CU22559A1 (es) * | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
NZ508366A (en) * | 1998-05-01 | 2004-03-26 | Chiron Corp | Neisseria meningitidis antigens and compositions |
MXPA02004283A (es) * | 1999-10-29 | 2002-10-17 | Chiron Spa | Peptidos antigenicos neisseriales. |
GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
-
2003
- 2003-12-03 CU CU2002008620030286A patent/CU23236A1/es unknown
-
2004
- 2004-12-01 AR ARP040104482A patent/AR046937A1/es unknown
- 2004-12-02 DE DE602004025377T patent/DE602004025377D1/de active Active
- 2004-12-02 NZ NZ547521A patent/NZ547521A/xx unknown
- 2004-12-02 WO PCT/CU2004/000016 patent/WO2005054282A1/es active Application Filing
- 2004-12-02 AU AU2004294377A patent/AU2004294377A1/en not_active Abandoned
- 2004-12-02 CN CNB2004800358798A patent/CN100549027C/zh not_active Expired - Fee Related
- 2004-12-02 AT AT04802608T patent/ATE456573T1/de not_active IP Right Cessation
- 2004-12-02 US US10/580,888 patent/US20070128230A1/en not_active Abandoned
- 2004-12-02 KR KR1020067011597A patent/KR20060124625A/ko not_active Application Discontinuation
- 2004-12-02 BR BRPI0417334-1A patent/BRPI0417334A/pt not_active IP Right Cessation
- 2004-12-02 RU RU2006123414/13A patent/RU2335505C2/ru not_active IP Right Cessation
- 2004-12-02 EP EP04802608A patent/EP1693379B1/en active Active
- 2004-12-02 CA CA002547537A patent/CA2547537A1/en not_active Abandoned
-
2006
- 2006-06-01 ZA ZA200604492A patent/ZA200604492B/en unknown
- 2006-06-28 NO NO20063017A patent/NO20063017L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005054282A1 (es) | 2005-06-16 |
AU2004294377A1 (en) | 2005-06-16 |
RU2006123414A (ru) | 2008-01-10 |
CN100549027C (zh) | 2009-10-14 |
ZA200604492B (en) | 2007-05-30 |
ATE456573T1 (de) | 2010-02-15 |
US20070128230A1 (en) | 2007-06-07 |
CU23236A1 (es) | 2007-09-26 |
AR046937A1 (es) | 2006-01-04 |
EP1693379B1 (en) | 2010-01-27 |
NZ547521A (en) | 2009-07-31 |
RU2335505C2 (ru) | 2008-10-10 |
BRPI0417334A (pt) | 2007-03-27 |
DE602004025377D1 (de) | 2010-03-18 |
KR20060124625A (ko) | 2006-12-05 |
CN1890261A (zh) | 2007-01-03 |
CA2547537A1 (en) | 2005-06-16 |
EP1693379A1 (en) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007149715A3 (en) | Novel dna sequences, vectors and proteins of avian influenza hemagglutinin | |
NO20044940L (no) | Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet | |
NO20064953L (no) | Human GLP-1 mimetilegemer, sammensetninger, fremgangsmater og anvendelser | |
WO2007054279A3 (en) | Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions | |
DK2010563T3 (da) | Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi | |
WO2008033375A3 (en) | Long lasting drug formulations | |
KR20050053732A (ko) | 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물 | |
CY1109841T1 (el) | Φορεις εμβολιου αδενοϊου χιμπατζη | |
TNSN07087A1 (en) | Stable liquid formulations of plasmid dna | |
WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
NO20063017L (no) | Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer | |
WO2007059931A8 (en) | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions | |
BR0309570A (pt) | Fatores camp quiméricos para vacinação contra infecção por streptococcus | |
NO20072854L (no) | Acylerte nonadepsipeptider anvendt som lysobaktinderivater | |
ATE473283T1 (de) | Dna-expressionsvektoren | |
GB2458057A (en) | Francisella strain for live vaccine | |
NO20051561L (no) | Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. | |
CY1107560T1 (el) | Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο | |
WO2021158755A3 (en) | Leptospiral proteins and uses thereof | |
NO20063020L (no) | Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer | |
Chakraborty et al. | Identification of promising CD8 and CD4 T cell epitopes for peptide vaccine formulation against SARS-CoV-2 | |
WO2007112702A3 (es) | Composición farmacéutica que comprende la proteína nmb0938 | |
WO2019059817A9 (en) | VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA | |
NO20083318L (no) | Farmasoytiske sammensetninger inneholdende protein NMA0939 | |
ES2401276A1 (es) | Utilización de una construcción genica y/o peptídica para la fabricación de una vacuna para la prevención y/o tratamiento de la infección causada por el virus de la peste porcina africana (vppa). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |